title: [The latest recommendations on the use of new oral anticoagulants in routine practice].
abstract: The use of non-vitamin K antagonist oral anticoagulants (NOACs) has become a breakthrough in anticoagulant treatment and it is expected to rise significantly in upcoming years. The use of conventional anticoagulants have several limitations: subcutaneous administration of heparin, or close monitoring of INR during application of vitamin K antagonists. In the last decade, target-specific oral anticoagulants (TSOAC) including dabigatran, rivaroxaban, apixaban, edoxaban have been marketed for prophylaxis and treatment. Therefore, it is crucial to understand the potential uses, side effects, and management of these agents in routine practice. NOACs have major pharmacologic advantages, including a rapid onset and offset of action, fewer drug interactions than conventional anticoagulants, and predictable pharmacokinetics. These agents are gaining popularity among both physicians and patients because of their easiness of administration and the eliminating the requirement for regular coagulation monitoring. In this review, we focus on discussing practical recommendations for the use of NOACs and the risks and benefits of incorporating them into routine practice.
authors: Klinika Kardiologii Interwencyjnej i Zaburzeń Rytmu Serca, Uniwersytet Medyczny w Łodzi.
authors: Michał
authors: M
authors: Witkowski
authors: Zakład Hematologii Doświadczalnej Uniwersytet Medyczny w Łodzi.
authors: Magdalena
authors: M
authors: Witkowska
authors: Zakład Hematologii Doświadczalnej Uniwersytet Medyczny w Łodzi.
authors: Piotr
authors: P
authors: Smolewski
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D000069604:Dabigatran / Q000627:therapeutic use; D006801:Humans; D010818:Practice Patterns, Physicians'; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D000069552:Rivaroxaban / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban